



## Mellen Center Currently Enrolling Treatment Trials

**Study Name:** A Phase I study to assess the feasibility, safety, and tolerability of autologous mesenchymal stem cell transplantation in patients with relapsing forms of multiple sclerosis

**Primary Investigator:** Jeffrey Cohen, M.D.

**Purpose:** The main purpose of this study is to evaluate to feasibility, safety, and tolerability of autologous mesenchymal stem cell transplantation in multiple sclerosis

**Entry requirements:** All participants must be between 18 and 55, have a relapsing form of MS, have moderate disability, be able to walk, have involvement of the visual system and documented disease activity within the last 2 years

**Duration:** Subjects will participate for approximately 8 months.

**Study Assessments:** The study is open label, all participants will receive the same treatment Participants will have frequent study visits

All participants will have bone marrow taken from their hip. Mesenchymal stem cells will be isolated from the bone marrow, which will be grown in culture so that there are an increased number of cells. The cells will be infused into the original participants arm by IV. Intensive safety monitoring will occur in the days and weeks following infusion.

EDSS, brain MRI scan, the 9Hole Peg Test, Timed 25-Foot Walk, optical coherence tomography, visual evoked potential, EKG, chest X-ray, physical and neurological examinations, vital signs, laboratory, adverse events, medication monitoring will occur for all participants.

For more information, please contact:

Cynthia Schwanger, RN, at [schwanc@ccf.org](mailto:schwanc@ccf.org) or

Sarah Planchon Pope, PhD, CCRP [planchs@ccf.org](mailto:planchs@ccf.org)